Centessa Pharmaceuticals plc (CNTA) — Analyst outlook / Analyst consensus target is. Based on 14 analyst ratings, the consensus is bullish — 9 Buy, 5 Hold.
The consensus price target is $38.60 (low: $35.00, high: $42.00), representing a downside of 2.5% from the current price $39.59.
Analysts estimate Earnings Per Share (EPS) of $-1.53 and revenue of $0.02B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.06 vs est $-1.53 (missed -35%). 2025: actual $-1.46 vs est $-1.36 (missed -7.4%). Analyst accuracy: 84%.
CNTA Stock — 12-Month Price Forecast
$38.60
▼ -2.50% Downside
Average Price Target
Based on 14 Wall Street analysts offering 12-month price targets for Centessa Pharmaceuticals plc, the average price target is $38.60, with a high forecast of $42.00, and a low forecast of $35.00.
The average price target represents a -2.50% change from the last price of $39.59.
Highest Price Target
$42.00
Average Price Target
$38.60
Lowest Price Target
$35.00
CNTA Analyst Ratings
Buy
Based on 14 analysts giving stock ratings to Centessa Pharmaceuticals plc in the past 3 months
EPS Estimates — CNTA
84%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.06
vs Est –$1.53
▼ 25.9% off
2025
Actual –$1.46
vs Est –$1.36
▼ 6.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — CNTA
87%
Analyst Accuracy
Accurate
1 year compared
Actual vs Estimate
2025
Actual $0.015B
vs Est $0.013B
▲ 12.6% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
